Form 4: Zimmer Biomet Director Christopher Begley Reports Acquisition of Phantom Stock Units

Director Christopher B. Begley reports acquiring phantom stock units in Zimmer Biomet Holdings, Inc. through a deferred compensation plan.

Summary

• Christopher B. Begley, a director of Zimmer Biomet Holdings, Inc., reported the acquisition of 451.977 phantom stock units on March 31, 2024.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
• The reporting person directly owns 18,939.967 derivative securities following the reported transaction.

Sentiment

Score: 7

Explanation: The sentiment is neutral as it reflects a routine transaction related to director compensation. There are no indications of positive or negative implications for the company's performance.

Future Outlook

The phantom stock units will be settled in cash within sixty days after cessation of the reporting person's service as a Director.

Industry Context

This filing is a routine disclosure of a director's compensation and holdings in the company, which is common in publicly traded companies. It provides transparency to investors regarding the alignment of interests between management and shareholders.

Comparison to Industry Standards

• Director compensation packages often include stock options, restricted stock units, or phantom stock units to align their interests with shareholders.
• Deferred compensation plans are a common way for companies to provide additional benefits to directors and key employees.
• The specifics of these plans vary widely across companies and industries.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates